Drug intelligence / Profile preview

SR-B + epratuzumab

Development stage: Unknown
Lead developer: Gilead Sciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

SR-B + epratuzumab is a combination drug consisting of two components: - **SR-B** (identity and mechanism not established from available sources; likely a code name for an investigational agent or compound). - **Epratuzumab**, a recombinant humanized monoclonal antibody that targets CD22—a cell surface glycoprotein expressed on mature B-cells and many malignant B-cells. Epratuzumab binds specifically to the third Ig-like domain of CD22 and exerts its antitumor activity primarily through antibody-dependent cellular cytotoxicity (ADCC). It acts as a B-cell modulator by inhibiting B-cell receptor signaling and selectively modifying B-cell activation and function. Epratuzumab has been investigated in the treatment of non-Hodgkin's lymphoma (NHL), precursor cell lymphoblastic leukemia-lymphoma, and systemic lupus erythematosus[1][2][3][5][7].

Brand names: LymphoCide
Other names: IMMU 103IMMU103IMMU-103IMMU LL2AMG 412AMG412AMG-412hCD22hCD-22hCD 22Humanised monoclonal antibody LL2Humanized anti-CD22 monoclonal antibody IgG1Epratucyn

Targets

CD22 (Cluster of Differentiation 22)

Beyond the preview

Go deeper on SR-B + epratuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SR-B + epratuzumab.

Explore the full profile